Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Community-Acquired Pneumonia |
Dose: Intravenous/Intramuscular – 1 g Frequency: once daily Duration: up to 14 days Note: after greater than or equal to 3 days of parenteral therapy, may be switched to appropriate by mouth regimen if patient improves clinically |
|
Indication: Complicated Urinary Tract Infections (Including Pyelonephritis) |
Dose: Intravenous/Intramuscular – 1 g Frequency: once daily Duration: up to 14 days Note: after greater than or equal to 3 days of parenteral therapy, may be switched to appropriate by mouth regimen if patient improves clinically |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Community-Acquired Pneumonia, Complicated Urinary Tract Infections (Including Pyelonephritis) Age: 3-12 years |
Dose: Intravenous/Intramuscular – 15 mg/kg Frequency: every 12 hours Duration: up to 14 days Note: not to exceed 1 g every 12 hours; after 3 or more days of parenteral therapy, may be switched to appropriate by mouth (oral) regimen if patient improves clinically |
|
Indication: Community-Acquired Pneumonia, Complicated Urinary Tract Infections (Including Pyelonephritis) Age: greater than 12 years |
Dose: Intravenous/Intramuscular – 1 g/day Duration: up to 14 days Note: after 3 or more days of parenteral therapy, may be switched to appropriate by mouth (oral) regimen if patient improves clinically |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment with Creatinine Clearance greater than 30 mL/min/1.73 m2 |
Dose: Intravenous – dosage adjustment not necessary Note: Dosage adjustment not necessary |
|
Condition: Renal impairment with Creatinine Clearance less than 30 mL/min/1.73 m2 and end-stage renal disease |
Dose: Intravenous – 500 mg Frequency: once daily |
Administration
- For IV infusion, infuse over 30 minutes
- For IM injection, inject into large muscle
Side Effect
- Diarrhea (2-12%)
- Elevated liver function tests (LFTs) (7-9%)
- Nausea (6-9%)
- Headache (6-7%)
- Infused vein complications (5-7%)
- Increased platelet count (4-7%)
- Increased alkaline phosphatase (4-7%)
- Altered mental status (3-5%)
- Fever (2-5%)
- Abdominal pain (4%)
- Vomiting (4%)
- Constipation (3-4%)
- Insomnia (3%)
- Swelling or edema (3%)
- Drug rash with eosinophilia and systemic symptoms (DRESS syndrome) (2-3%)
- Rash (2-3%)
- Vaginitis (1-3%)
- Dizziness (2%)
- Phlebitis or thrombophlebitis (1.5-2%)
- Pruritus (1-2%)
- Tachycardia (1-2%)
- Acid regurgitation (1-2%)
- Eosinophilia (1-2%)
- Hypotension (1-2%)
- Erythema (1-2%)
- Hypertension (0.7-2%)
- Chest pain (1%)
- Dyspepsia (1%)
- Fatigue (1%)
- Anxiety (0.8-1%)
- Oral candidiasis (0.1-1%)
- Pseudomembranous colitis
- Stevens-Johnson syndrome
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Valproic acid
|
May decrease plasma levels, increasing risk of seizures
|
|
Probenecid
|
Increased plasma concentrations
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
No specific contraindications listed
|
Monitor for general drug reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Diluted solutions are physically and chemically stable for 6 hours at room temperature (25°C) or for 24 hours at 2 to 8°C (in a refrigerator). Solutions should be used within 4 hours of their removal from the refrigerator. Do not freeze solution. Do not store above 25°C.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.